Lobbying pays off as drug industry hits jackpot with health overhaul

[Better Believe It]

THE INFLUENCE GAME: Lobbying pays off as drug industry hits jackpot with health overhaul.
By ALAN FRAM
Associated Press Writer
March 29, 2010

Chalk one up for the pharmaceutical lobby. The U.S. drug industry fended off price curbs and other hefty restrictions in President Barack Obama's health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage.

To be sure, the law also levies taxes and imposes other costs on pharmaceutical companies, leaving its final impact on the industry's bottom line uncertain. A recent analysis by Goldman Sachs, the Wall Street firm, suggests the overhaul could mean "a manageable hit" of tens of billions of dollars over the coming decade while bolstering the value of drug-company stocks. Others expect profits, not losses, of the same magnitude.

Either way, pharmaceutical lobbyists won new federal policies they coveted and set a trajectory for long-term industry growth. Privately, several of them say their biggest triumph was heading off Democrats led by Rep. Henry Waxman, D-Calif., who wanted even more money from their industry to finance the health care system's expansion.

Costly brand-name biotech drugs won 12 years of protection against cheaper generic competitors, a boon for products that comprise 15 percent of pharmaceutical sales. The industry will have to provide 50 percent discounts beginning next year to Medicare beneficiaries in the "doughnut hole" gap in pharmaceutical coverage, but those price cuts plus gradually rising federal subsidies will mean more elderly people will purchase more drugs.

Edited to conform to DU's rules for fairuse of copyrighted material - Lithos, DU Moderator

Read the full article at:

http://hosted.ap.org/dynamic/stories/U/US_HEALTH_OVERHAUL_PHARMAS_BIG_WIN?SITE=WIJAN&SECTION=HOME&TEMPLATE=DEFAULT